Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416

Cancer Letters

Volumn 270, Issue 2, 2008, Pages 260-268

  Katanasaka, Yasufumi ^a,b   Ida, Tomoko ^a   Asai, Tomohiro ^a   Shimizu, Kosuke ^a   Koizumi, Fumiaki ^b   Maeda, Noriyuki ^c   Baba, Kazuhiko ^d   Oku, Naoto ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c Nippon Fine Chemical Co Ltd   (Japan)

^d TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Angiogenesis; Antiangiogenic therapy; APRPG modified liposomes; Drug delivery systems; SU5416

Indexed keywords

ANGIOGENESIS INHIBITOR; CREMOPHOR; HEMOGLOBIN; LIPOSOME; SEMAXANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; ENCAPSULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NEOPLASM; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; DRUG STABILITY; ENDOTHELIAL CELLS; HEMOLYSIS; HUMANS; INDOLES; LIPIDS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; PARTICLE SIZE; PYRROLES; SOLUBILITY; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 52149099655     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.05.009     Document Type: Article

References (28)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
2. Neri D., and Bicknell R. Tumour vascular targeting. Nat. Rev. Cancer 5 (2005) 436-446
3. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
4. Spannuth W.A., Sood A.K., and Coleman R.L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat. Clin. Pract. Oncol. 5 (2008) 194-204
5. Fong T.A., Shawver L.K., Sun L., Tang C., App H., Powell T.J., Kim Y.H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K.P., and McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59 (1999) 99-106
6. Mendel D.B., Schreck R.E., West D.C., Li G., Strawn L.M., Tanciongco S.S., Vasile S., Shawver L.K., and Cherrington J.M. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin. Cancer Res. 6 (2000) 4848-4858
7. Zangari M., Anaissie E., Stopeck A., Morimoto A., Tan N., Lancet J., Cooper M., Hannah A., Garcia-Manero G., Faderl S., Kantarjian H., Cherrington J., Albitar M., and Giles F.J. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin. Cancer Res. 10 (2004) 88-95
8. Arora A., and Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315 (2005) 971-979
9. Ye C., Sweeny D., Sukbuntherng J., Zhang Q., Tan W., Wong S., Madan A., Ogilvie B., Parkinson A., and Antonian L. Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. Toxicol. In Vitro 20 (2006) 154-162
10. Gelderblom H., Verweij J., Nooter K., and Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37 (2001) 1590-1598
11. Zou Y., Fu H., Ghosh S., Farquhar D., and Klostergaard J. Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin. Cancer Res. 10 (2004) 7382-7391
12. Stadler W.M., Cao D., Vogelzang N.J., Ryan C.W., Hoving K., Wright R., Karrison T., and Vokes E.E. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin. Cancer Res. 10 (2004) 3365-3370
13. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
14. Cheong I., Huang X., Thornton K., Diaz Jr. L.A., and Zhou S. Targeting cancer with bugs and liposomes: ready, aim, fire. Cancer Res. 67 (2007) 9605-9608
15. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
16. Nornoo A.O., and Chow D.S. Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. Int. J. Pharm. 349 (2008) 117-123
17. Nobs L., Buchegger F., Gurny R., and Allemann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Pharm. Sci. 93 (2004) 1980-1992
18. Maeda N., Miyazawa S., Shimizu K., Asai T., Yonezawa S., Kitazawa S., Namba Y., Tsukada H., and Oku N. Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs. Biol. Pharm. Bull. 29 (2006) 1936-1940
19. Maeda N., Takeuchi Y., Takada M., Sadzuka Y., Namba Y., and Oku N. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J. Control. Release 100 (2004) 41-52
20. Oku N., Asai T., Watanabe K., Kuromi K., Nagatsuka M., Kurohane K., Kikkawa H., Ogino K., Tanaka M., Ishikawa D., Tsukada H., Momose M., Nakayama J., and Taki T. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene 21 (2002) 2662-2669
21. Ichikawa K., Urakami T., Yonezawa S., Miyauchi H., Shimizu K., Asai T., and Oku N. Enhanced desensitization efficacy by liposomal conjugation of a specific antigen. Int. J. Pharm. 336 (2007) 391-395
22. Guggi D., Langoth N., Hoffer M.H., Wirth M., and Bernkop-Schnurch A. Comparative evaluation of cytotoxicity of a glucosamine-TBA conjugate and a chitosan-TBA conjugate. Int. J. Pharm. 278 (2004) 353-360
23. Crosasso P., Ceruti M., Brusa P., Arpicco S., Dosio F., and Cattel L. Preparation characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Control. Release 63 (2000) 19-30
24. Kim S. Liposomes as carriers of cancer chemotherapy, current status and future prospects. Drugs 46 (1993) 618-638
25. Sharma A., Mayhew E., Bolcsak L., Cavanaugh C., Harmon P., Janoff A., and Bernacki R.J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer 71 (1997) 103-107
26. Yang T., Cui F.D., Choi M.K., Cho J.W., Chung S.J., Shim C.K., and Kim D.D. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int. J. Pharm. 338 (2007) 317-326
27. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., Corfas G., and Folkman J. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10 (2004) 255-261
28. Vicent M.J., and Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 24 (2006) 39-47